Skip to main content

Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Site Search
Reata Pharmaceuticals Inc. logo
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window

Our Science

We explore the frontiers of science to further human health.

  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations

Our Technologies

Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.

Nrf2 Activators

nrf2 2flu

©Reata Pharmaceuticals, Inc.
Kelch domain of Keap1
PDB Code 2FLU

Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling (1-3).

HSP90 Modulators

hsp90

©Reata Pharmaceuticals, Inc.
Middle segment of HSP90
PDB Code 1USV

We are developing a novel class of molecules that target pathways involved in the cellular stress response. Our lead product candidate, Cemdomespib, and related analogs have shown promising effects in animal models of neurological disease. Cemdomespib is in development for Diabetic Peripheral Neuropathic Pain.

discover oval

Our Pipeline

Reata’s development programs now have an approved product in addition to creating a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases.

Preclinical
Phase 1
Phase 2
Pivotal
Regulatory Review
FDA Approved
Neurology
Friedreich's Ataxia | SKYCLARYSa Friedreich's Ataxia
SKYCLARYSa

Follow the links to:

  • Learn more about FA.
Friedreich's Ataxia | Omaveloxolone in Europeb Friedreich's Ataxia
Omaveloxolone in Europeb

Follow the links to:

  • Learn more about FA.
DPNPc | Cemdomespib DPNPc
Cemdomespib

Follow the links to:

  • Learn more about DPNP.
  • Learn about Cemdomespib.
Nrf2 Activator | RTA 415 Nrf2 Activator
RTA 415

Follow the links to:

  • Learn about our Nrf2 activators.
Nrf2 Activator | RTA 417 Nrf2 Activator
RTA 417

Follow the links to:

  • Learn about our Nrf2 activators.

aSKYCLARYS (omaveloxolone) is approved by the U.S. FDA and not approved by any other regulatory authority outside the U.S. bMarketing Authorisation Application (MAA) submitted in 4Q22 in Europe. cDiabetic peripheral neuropathic pain (DPNP). Reata plans to initiate a Phase 2 trial of Cemdomespib in patients with DPNP in the third quarter of 2023.

Cemdomespib, RTA 415, and RTA 417 are investigational drugs. Safety and efficacy have not been established by any agency.

References

References

  1. Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018) The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev 98, 1169-1203
  2. Hayes, J. D., and Dinkova-Kostova, A. T. (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci 39, 199-218
  3. Holmstrom, K. M., Kostov, R. V., and Dinkova-Kostova, A. T. (2016) The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol 1, 80-91
back to top
Palo Duro Canyon
Reata Pharmaceuticals Inc. logo

Intended for US residents only.

  • Sitemap
  • Legal Message
  • Privacy Notice
  • Social Media Disclosure
  • Contact Us
Powered By Q4 Inc. 5.112.1.9 (opens in new window)

© Reata Pharmaceuticals, Inc., All Rights Reserved. | US-NON-2100018 | 09/2023

Stay Connected Mobile

  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window